ライフサイエンスコーパス: hemorrhagic complication

1 of clotting factors, which may cause profuse hemorrhagic complications.

2 ACT, however, does not predict hemorrhagic complications.

3 tion but with higher risks of infectious and hemorrhagic complications.

4 ed their differential impact on ischemic and hemorrhagic complications.

5 osage, anticoagulation control, and risk for hemorrhagic complications.

6 infection, but with more thromboembolic and hemorrhagic complications.

7 ing time (ACT) for prevention of ischemic or hemorrhagic complications.

8 nonfatal MI, rehospitalization, stroke, and hemorrhagic complications.

9 the potential for gastrointestinal upset and hemorrhagic complications.

10 ion is occasionally needed to treat or avoid hemorrhagic complications.

11 rombin have been anecdotally associated with hemorrhagic complications.

12 and 1 (4%) with a choroidal lesion suffered hemorrhagic complications.

13 icial for patients with an increased risk of hemorrhagic complications.

14 model and were not associated with untoward hemorrhagic complications.

15 13%) patients but there was no PP-related or hemorrhagic complications.

16 in prothrombin times, and in the absence of hemorrhagic complications.

17 s randomized to the TriActiv System had more hemorrhagic complications (10.9% vs. 5.4%; p = 0.01).

18 ercent, P<0.001), but they had more frequent hemorrhagic complications (17 percent vs. 5 percent, P<0

19 In 8 patients, hemorrhagic complications (5 autoantibodies and 3 bovine

20 anemia more frequently developed in-hospital hemorrhagic complications (6.2% vs. 2.4%, p = 0.002), ha

21 patients with major bleeding or at risk for hemorrhagic complications, administration of platelet co

22 ction of CXCL13 and IL-6, and thrombotic and hemorrhagic complications affecting multiple organs with

23 With the exception of severe ischemic or hemorrhagic complications affecting the abdominal organs

24 al death and the development of ischemic and hemorrhagic complications and ICU-acquired infections.

25 The association between hemorrhagic complications and mortality may explain the

26 is markedly limited owing to concerns about hemorrhagic complications and the requirement that tPA b

27 Clinically significant hemorrhagic complications and thrombocytopenia were infr

28 ion of dabigatran to avoid the deaths due to hemorrhagic complications and thromboembolic stroke in c

29 Hemorrhagic complications and transfusion requirements w

30 No patient developed a significant hemorrhagic complication, and each patient's platelet co

31 cessful reperfusion, good clinical outcomes, hemorrhagic complications, and mortality.

32 Hemorrhagic complications are frequently implicated clin

33 rently employed have encountered significant hemorrhagic complications, as well as complications from

34 educes both cerebrovascular permeability and hemorrhagic complications associated with late administr

35 t correlated with an increased occurrence of hemorrhagic complications, but bleeding complications di

36 It is characterized by severe hemorrhagic complications due in part to excessive fibri

37 Hemorrhagic complications during EUS-guided pseudocyst d

38 (8.7%) patients exhibited severe ischemic or hemorrhagic complications during the ICU stay.

39 nticoagulants, there is an increased risk of hemorrhagic complications for these men.

40 To discuss thrombotic and hemorrhagic complications from angiogenesis inhibitors a

41 ildren, sisters, both with severe, recurrent hemorrhagic complications from factor VII deficiency, su

42 Hemorrhagic complications from intracranial pressure mon

43 Hemorrhagic complications have been strongly linked with

44 GIB is a potential hemorrhagic complication in patients with ACS treated wi

45 nor functioned adequately, and there were no hemorrhagic complications in any of the recipients.

46 ac performance with a low incidence of major hemorrhagic complications in patients with documented es

47 No threshold was found for hemorrhagic complications in patients with or without gl

48 milar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina

49 Both ischemic and hemorrhagic complications increase mortality rate in acu

50 e its association with a higher frequency of hemorrhagic complications, intraarterial infusion of uro

51 ]; P < .001) and not significantly different hemorrhagic complications (OAC: 14/172 [8.1%] vs no OAC:

52 Significant hemorrhagic complications occur with living kidney donat

53 Hemorrhagic complications occurred in 10 patients (1.8 p

54 croL (platelets), no secondary infectious or hemorrhagic complications occurred.

55 possibility that rupture represents an early hemorrhagic complication of thrombolytic therapy should

56 ion of annexin II may be a mechanism for the hemorrhagic complications of APL.

57 tion of antiplatelet therapy and the risk of hemorrhagic complications of having a surgical procedure

58 To define hemorrhagic complications of living kidney donation, a s

59 of ocular complications, including uveitis, hemorrhagic complications, optic disc edema, and dry eye

60 Hemorrhagic complication rates in pediatric stroke are u

61 Two patients (0.7%) had a hemorrhagic complication requiring transfusion, and anot

62 clinical guidelines to minimize the risk of hemorrhagic complications such as epidural hematoma.

63 f stent thrombosis, although there were more hemorrhagic complications than with aspirin alone.

64 F) plays an important role in triggering the hemorrhagic complications that characterize EBOV infecti

65 Unlike major hemorrhagic complications, there is no evidence that the

66 Hemorrhagic complications were infrequent, with no signi

67 Hemorrhagic complications were noted, and the Fisher exa

68 Where data were available, hemorrhagic complications were rare in intracranial pres

69 No major hemorrhagic complications were reported.

70 ation of vision, resolution of exudative and hemorrhagic complications with regression of polyps in p

71 Rates of hemorrhagic complications with the two drugs were simila

72 o suggest a higher risk of thromboembolic or hemorrhagic complications with use of dabigatran for per